Clinical OMICS

MAR-APR 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1093879

Contents of this Issue

Navigation

Page 41 of 51

www.clinicalomics.com March/April 2019 Clinical OMICs 40 New Products Precision Medicine Informatics Charts Patient Journey XIFIN unveiled VisualStrata, a precision medicine informatics platform that curates and visualizes diagnostic, clinical, and financial data to document the patient journey through diagnosis, treatment and outcomes. The platform collates structured and unstructured data from disparate systems into a single source, to provide insights into disease treatments for personalized care decisions. It also supports strategic organizational objectives such as clinical improvement initiatives, efficiency pro- grams, physician engagement, and population health efforts. VisualStrata consolidates rich patient datasets from multiple sources for the development of real-world evidence, which can be used to establish clinical utility and lead to new disease treatment insights. It also provides healthcare quality reporting, vital in today's value-based healthcare environment, and also temporal record and case management that accurately documents each patient's journey through the healthcare system. XIFIN www.xifin.com Generate PCR-Amplified cDNA Libraries Dolomite Bio, a provider of single-cell technolo- gies, announced the launch of a new scRNA-Seq Reagent Kit to expand its Nadia Instrument port- folio. The new kit is designed to enable robust and reliable generation of PCR amplified cDNA libraries on the Nadia Instrument, allowing high-through- put gene expression profiling of heterogenous cell populations. The kit contains all the consumables required to create amplified cDNA libraries, allow- ing researchers to achieve reproducible single cell data sets at low sequencing costs. Unlike other solutions, this set up also gives users the ability to adjust the number of single cell cDNA libraries prior to sequencing, helping to ensure cost-efficient sin- gle-cell analysis. Dolomite Bio www.dolomite-bio.com Automate Early Steps for DNA and RNA Protein Sample Processing Qiagen has launched QIAcube Connect to enable research laboratories to automate the first steps of molecular research workflows using Qiagen's spin column technologies for DNA, RNA, and protein sample processing. Automation with QIAcube Connect assures standard- ization in purification of multiple sample types and frees researchers from repetitive manual processing. QIAcube Connect automates the lysis, bind, wash and elute steps of the Qiagen spin columns for DNA, RNA, and protein sample processing; is fully compatible with a range of Qiagen sample technologies; and can be used to automate more than 80 Qiagen kits with more than 3,000 proven protocols. Full connectivity allows researchers to stay connected with their instrument, enables quick response times, protocol review, and the ability to remotely monitor runs. Fully automated workta- ble decontamination is built-in. Protocol controls and managed users allow for advanced data protection, while digital and barcode-en- abled sample tracking and pre-run checks provide confidence in results. QIAGEN www.qiagen.com Non-Invasive Prenatal Screening Test Invitae has added non-invasive prenatal screening (NIPS) to the its women's health genetic testing services. In combination with the expanded carrier screening (ECS), Invi- tae now offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing available for patients who need it. Invitae's NIPS quickly analyzes cell-free DNA to assess whether a pregnancy (singleton or twin) is at increased risk for the three most common chromosomal disorders, including Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome) and Trisomy 13 (Patau syndrome). Microdeletion and sex chromosome analysis can be added at no additional charge. Invitae is combining its new NIPS offering with the Invitae Carrier Screen in one specimen collection kit. Invitae's comprehensive carrier screen uses advanced sequencing to identify changes in 301 genes linked to serious genetic disorders, including cystic fibrosis (CF), spinal muscular atrophy (SMA) and many other life-threatening disorders. Invitae www.invitae.com

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2019